FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W332341569> ?p ?o ?g. }

• W332341569 endingPage "57" @default.
• W332341569 startingPage "1449" @default.
• W332341569 abstract "The apoptosis-regulating proteins Bcl-2, Bax, Bcl-X, Bak, and Mcl-1 were examined by immunohistochemical methods in 48 archival specimens of adenocarcinoma of the stomach, and the results were correlated with tumor histology (intestinal versus diffuse pattern) and clinical stage (early- versus late-stage disease, ie, stages I and II versus stage III). Tumor cells containing immunostaining for the anti-apoptotic proteins Bcl-2, Bcl-X, and Mcl-1 were present in 26 (54%), 41 (85%), and 36 (75%) of the 48 cases evaluated, respectively, whereas immunopositivity for the pro-apoptotic proteins Bax and Bak was found in 44 (92%) and 42 (88%) specimens Comparisons of these immunostaining results with tumor histology revealed statistically significant differences for Bax (P = 0.03), Bcl-X (P = 0.003), and Mcl-1 (P = 0.005), which were all more frequently immunopositive for tumors with an intestinal than a diffuse histological pattern (chi 2 analysis). In addition, the percentage of immunopositive tumor cells was significantly higher for Bcl-X (62 +/- 6% versus 45 +/- 6%, mean +/- SE, P = 0.01) and for Mcl-1 (48 +/- 6% versus 30 +/- 6%; P = 0.04) in tumors with intestinal versus diffuse histology (unpaired t-test). In contrast, the percentage of Bcl-2-immunopositive tumor cells was higher in tumors with diffuse histology compared with intestinal (32 +/- 5% versus 12 +/- 5%; P = 0.01), whereas the percentages of Bax- and Bak-immunopositive tumor cells were not significantly different between these two histological types. In 34 specimens, residual normal gastric epithelial cells (foveolar cells) were present for direct comparisons of immunointensity with tumor cells. The immunointensity for the Bcl-2, Bcl-X, and Mcl-1 proteins was stronger in tumor cells compared with normal foveolar cells in 7 (21%), 15 (44%), and 8 (2.1%) of 34 cases, respectively, whereas the immunointensity of the proapoptotic proteins Bax and Bak was reduced compared with normal cells in 8 (24%) and 24 (71%) cases. Immunointensity, however, did not correlate with histology. clinical stage was not significantly associated with the presence or absence of immunopositive tumor cells, the percentage of immunopositive cells, or immunointensity. Taken together, these results establish for the first time that several Bcl-2 family proteins are expressed in gastric adenocarcinomas and suggest that the repertoire of these proteins may differ depending on the histological type. The findings therefore support the notion that the intestinal and diffuse types of gastric cancer arise at least in part through different mechanisms." @default.
• W332341569 created "2016-06-24" @default.
• W332341569 creator A5011956644 @default.
• W332341569 creator A5021543587 @default.
• W332341569 creator A5023882949 @default.
• W332341569 creator A5041051444 @default.
• W332341569 creator A5059438505 @default.
• W332341569 creator A5072504891 @default.
• W332341569 creator A5074329698 @default.
• W332341569 date "1996-11-01" @default.
• W332341569 modified "2023-10-06" @default.
• W332341569 title "Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach." @default.
• W332341569 cites W1480050981 @default.
• W332341569 cites W1496609997 @default.
• W332341569 cites W1497290886 @default.
• W332341569 cites W1529927626 @default.
• W332341569 cites W1539305121 @default.
• W332341569 cites W154264227 @default.
• W332341569 cites W1561506007 @default.
• W332341569 cites W1878608668 @default.
• W332341569 cites W1898236813 @default.
• W332341569 cites W1983072511 @default.
• W332341569 cites W1991865867 @default.
• W332341569 cites W2003301112 @default.
• W332341569 cites W2005174738 @default.
• W332341569 cites W2008597649 @default.
• W332341569 cites W2008898220 @default.
• W332341569 cites W2009183764 @default.
• W332341569 cites W2030312997 @default.
• W332341569 cites W2042928863 @default.
• W332341569 cites W2048428832 @default.
• W332341569 cites W2057257609 @default.
• W332341569 cites W2058591356 @default.
• W332341569 cites W2063176993 @default.
• W332341569 cites W2077270970 @default.
• W332341569 cites W2088187860 @default.
• W332341569 cites W2089883223 @default.
• W332341569 cites W2100522747 @default.
• W332341569 cites W2118008114 @default.
• W332341569 cites W2126699849 @default.
• W332341569 cites W2134979684 @default.
• W332341569 cites W2171725581 @default.
• W332341569 cites W2259568108 @default.
• W332341569 cites W26755955 @default.
• W332341569 cites W97746810 @default.
• W332341569 cites W2082134164 @default.
• W332341569 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1865280" @default.
• W332341569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8909234" @default.
• W332341569 hasPublicationYear "1996" @default.
• W332341569 type Work @default.
• W332341569 sameAs 332341569 @default.
• W332341569 citedByCount "53" @default.
• W332341569 countsByYear W3323415692012 @default.
• W332341569 countsByYear W3323415692013 @default.
• W332341569 countsByYear W3323415692014 @default.
• W332341569 countsByYear W3323415692015 @default.
• W332341569 countsByYear W3323415692017 @default.
• W332341569 countsByYear W3323415692018 @default.
• W332341569 countsByYear W3323415692020 @default.
• W332341569 crossrefType "journal-article" @default.
• W332341569 hasAuthorship W332341569A5011956644 @default.
• W332341569 hasAuthorship W332341569A5021543587 @default.
• W332341569 hasAuthorship W332341569A5023882949 @default.
• W332341569 hasAuthorship W332341569A5041051444 @default.
• W332341569 hasAuthorship W332341569A5059438505 @default.
• W332341569 hasAuthorship W332341569A5072504891 @default.
• W332341569 hasAuthorship W332341569A5074329698 @default.
• W332341569 hasConcept C121608353 @default.
• W332341569 hasConcept C142724271 @default.
• W332341569 hasConcept C190283241 @default.
• W332341569 hasConcept C204232928 @default.
• W332341569 hasConcept C2777546739 @default.
• W332341569 hasConcept C2779422922 @default.
• W332341569 hasConcept C2781182431 @default.
• W332341569 hasConcept C4224716 @default.
• W332341569 hasConcept C54355233 @default.
• W332341569 hasConcept C55493867 @default.
• W332341569 hasConcept C57742111 @default.
• W332341569 hasConcept C71924100 @default.
• W332341569 hasConcept C86803240 @default.
• W332341569 hasConceptScore W332341569C121608353 @default.
• W332341569 hasConceptScore W332341569C142724271 @default.
• W332341569 hasConceptScore W332341569C190283241 @default.
• W332341569 hasConceptScore W332341569C204232928 @default.
• W332341569 hasConceptScore W332341569C2777546739 @default.
• W332341569 hasConceptScore W332341569C2779422922 @default.
• W332341569 hasConceptScore W332341569C2781182431 @default.
• W332341569 hasConceptScore W332341569C4224716 @default.
• W332341569 hasConceptScore W332341569C54355233 @default.
• W332341569 hasConceptScore W332341569C55493867 @default.
• W332341569 hasConceptScore W332341569C57742111 @default.
• W332341569 hasConceptScore W332341569C71924100 @default.
• W332341569 hasConceptScore W332341569C86803240 @default.
• W332341569 hasIssue "5" @default.
• W332341569 hasLocation W3323415691 @default.
• W332341569 hasOpenAccess W332341569 @default.
• W332341569 hasPrimaryLocation W3323415691 @default.
• W332341569 hasRelatedWork W1991840061 @default.

• next